Opus, Viatris Unit Sue Sandoz to Block Copy of Ryzumvi Eye Drug

Copies of Ryzumvi proposed by Sandoz Inc. infringe eight patents that Opus Genetics Inc. licenses exclusively to Viatris Inc.’s FamyGen unit for eye drops used to reverse pupil dilation, a federal lawsuit said.

Opus and FamyGen Life Sciences Inc. allege the Sandoz Group AG subsidiary’s generic Ryzumvi infringes U.S. Patent Nos. 9,795,560, 10,278,918, 10,772,829, 11,090,261, 11,844,858, 11,400,077, 12,201,615, and 12,201,616, according to a complaint filed March 14 in the US District Court for the District of New Jersey.

• Five of the patents expire in January 2034, two in October 2039, and the ...